ReviewDermatology and therapy2025
Exploring the Experience of Black Americans Living with Hidradenitis Suppurativa in the United States Healthcare System: A Narrative Review.
Review in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Black Americans face persistent healthcare disparities due to a combination of structural, socioeconomic, and historical factors, which can lead to disparities in healthcare quality access and health outcomes. Hidradenitis suppurativa (HS) is a chronic inflammatory disease that is associated with high physical, socioeconomic, and emotional burdens. HS is an example of the broader heath disparities faced by Black patients in the USA. The overall prevalence of HS in the USA is estimated to be 0.1-1.7%, but the prevalence is more than threefold higher among Black individuals than among White individuals. Black patients with HS often have more severe disease than White patients but face longer diagnostic delays and have less access to specialized dermatologic care. By addressing the barriers to care faced by Black patients with HS, dermatologists and healthcare providers can reduce health disparities and improve outcomes for these patients. The objective of this clinical review is to provide an overview of the disparities in clinical burden, diagnostic delays, and treatment faced by Black patients with HS. We also provide commentary from the physician's perspective on factors that contribute to these health disparities and approaches to reduce barriers to appropriate HS care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.